标题
Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 4, Pages 1041
出版商
MDPI AG
发表日期
2018-03-31
DOI
10.3390/ijms19041041
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma
- (2018) Shingo Inaguma et al. HUMAN PATHOLOGY
- Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
- (2018) Namrata S. Patil et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- CD56 in the Immune System: More Than a Marker for Cytotoxicity?
- (2017) Heleen H. Van Acker et al. Frontiers in Immunology
- The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
- (2017) Christian M. Schürch et al. OncoImmunology
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas
- (2016) Christelle Combaz-Lair et al. HUMAN PATHOLOGY
- Malignant Mesothelioma Effusions Are Infiltrated by CD3 + T Cells Highly Expressing PD-L1 and the PD-L1 + Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab
- (2016) Swati Khanna et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)
- (2016) S. Cedrés et al. LUNG CANCER
- Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
- (2016) Leon P. Pradel et al. MOLECULAR CANCER THERAPEUTICS
- Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
- (2016) M. M. Awad et al. Cancer Immunology Research
- Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
- (2016) Elly Marcq et al. OncoImmunology
- Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
- (2015) A. Lo et al. CANCER RESEARCH
- Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Intratumoral macrophage phenotype and CD8 + T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma
- (2015) Robin Cornelissen et al. LUNG CANCER
- The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
- (2015) Hideki Ujiie et al. OncoImmunology
- Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
- (2015) Susana Cedrés et al. PLoS One
- Regulatory T cells in cancer immunotherapy
- (2014) Hiroyoshi Nishikawa et al. CURRENT OPINION IN IMMUNOLOGY
- Immunomodulation in cancer
- (2014) Joost PJJ Hegmans et al. CURRENT OPINION IN PHARMACOLOGY
- B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
- (2014) Aaron Scott Mansfield et al. Journal of Thoracic Oncology
- Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
- (2014) Robin Cornelissen et al. PLoS One
- New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas
- (2013) Brooke T. Mossman et al. AMERICAN JOURNAL OF PATHOLOGY
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation
- (2012) B. M. Burt et al. CLINICAL CANCER RESEARCH
- The emerging role of T cell cytokines in non-small cell lung cancer
- (2012) Markus F. Neurath et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes
- (2012) Kevin M. Friedman et al. JOURNAL OF IMMUNOTHERAPY
- Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network
- (2011) Qi Li et al. AMERICAN JOURNAL OF PATHOLOGY
- Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma
- (2011) Bryan M. Burt et al. CANCER
- Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma
- (2011) Adam J. Bograd et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients
- (2011) Kei Suzuki et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Malignant mesothelioma: Facts, Myths, and Hypotheses
- (2011) Michele Carbone et al. JOURNAL OF CELLULAR PHYSIOLOGY
- COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
- (2010) Joris D Veltman et al. BMC CANCER
- Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
- (2010) J D Veltman et al. BRITISH JOURNAL OF CANCER
- CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
- (2010) Noriyuki Yamada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
- (2010) Joris D. Veltman et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- IL4Rα + Myeloid-Derived Suppressor Cell Expansion in Cancer Patients
- (2009) Susanna Mandruzzato et al. JOURNAL OF IMMUNOLOGY
- Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
- (2009) G. Solinas et al. JOURNAL OF LEUKOCYTE BIOLOGY
- CD4 T cells: fates, functions, and faults
- (2008) J. Zhu et al. BLOOD
- Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
- (2008) Robbert G. van der Most et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
- (2008) Masaki Anraku et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now